68 results
8-K
EX-99.1
SRZN
Surrozen Inc
8 May 24
Surrozen Provides First Quarter 2024 Financial Results and Business Update
4:12pm
antibody based Wnt mimetic, to activate targeted cell regeneration in cornea endothelial dystrophies and dry eye disease
SOUTH SAN FRANCISCO, Calif., May 8 … activate the Wnt pathway for tissue repair and regeneration, today provided first quarter 2024 financial results and business updates.
“2024
424B5
SRZN
Surrozen Inc
25 Apr 24
Prospectus supplement for primary offering
4:28pm
maintenance and regeneration throughout the body, we have the potential to target a wide variety of severe diseases, including certain diseases
8-K
EX-99.1
f31qy yk5
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
8-K
EX-99.2
3gwho u9t
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
424B3
bwo904f70rl9fc9p
8 Nov 23
Prospectus supplement
4:27pm
8-K
EX-99.1
0jrqkb62e3x a5nc2k7
8 Nov 23
Surrozen Provides Third Quarter 2023 Financial Results
4:09pm
424B3
7liwm2je33zjxp 65x
9 Aug 23
Prospectus supplement
4:39pm
8-K
EX-99.1
t0d pfi3x3llotomq2
9 Aug 23
Surrozen Provides Second Quarter 2023 Financial Results
4:16pm
424B3
7bpw1iv5zrn dpktgr1
10 May 23
Prospectus supplement
4:47pm
8-K
EX-99.1
fr4xdw
10 May 23
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
4:14pm
424B3
pss2zi9xg1ejc58ku4w
7 Apr 23
Prospectus supplement
5:20pm
424B3
k8bcokrb5t4v8rpk
6 Apr 23
Prospectus supplement
5:15pm
POS AM
4mvm rxt7brms
31 Mar 23
Prospectus update (post-effective amendment)
4:52pm
POS AM
xl9tzq7bgslz236ahw8
31 Mar 23
Prospectus update (post-effective amendment)
9:09am